MedTrace Logo

Defining the Molecular Risk in Israeli Patients With Secondary Compared to Primary Myelofibrosis

NCT03402399 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 222

Last updated 2019-07-05

No results posted yet for this study

Summary

The aim of the study is to determine the rate of HMR mutations in PMF and secondary MF (post PV/ET) subjects, and correlate the rate of mutations with clinical features as known prognostic scores.

Conditions

  • Myelofibrosis, Primary
  • Myelofibrosis, Post PV
  • Myelofibrosis, Post ET

Interventions

OTHER

Molecular analysis

Blood test

Sponsors & Collaborators

  • Assaf-Harofeh Medical Center

    lead OTHER_GOV

Principal Investigators

  • Maya Koren-Michowitz, MD · Assaf-Harofeh Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-10
Primary Completion
2019-12-09
Completion
2020-12-09

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03402399 on ClinicalTrials.gov